+ND Capital exits CellPoint, via sale to Belgian biotech company Galapagos
“This deal is further validation of our strategy to invest in company creation in Europe," said Patrick Aebischer, Senior Partner at +ND Capital.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
